Your browser doesn't support javascript.
loading
Prism adaptation treatment for upper-limb complex regional pain syndrome: a double-blind randomized controlled trial.
Halicka, Monika; Vittersø, Axel D; McCullough, Hayley; Goebel, Andreas; Heelas, Leila; Proulx, Michael J; Bultitude, Janet H.
Afiliación
  • Halicka M; Centre for Pain Research, University of Bath, Bath, United Kingdom.
  • Vittersø AD; Department of Psychology, University of Bath, Bath, United Kingdom.
  • McCullough H; Centre for Pain Research, University of Bath, Bath, United Kingdom.
  • Goebel A; Department of Psychology, University of Bath, Bath, United Kingdom.
  • Heelas L; Department of Sport and Health Sciences, University of Exeter, Exeter, United Kingdom.
  • Proulx MJ; Department of Translational Medicine, Pain Research Institute, University of Liverpool, Liverpool, United Kingdom.
  • Bultitude JH; Department of Translational Medicine, Pain Research Institute, University of Liverpool, Liverpool, United Kingdom.
Pain ; 162(2): 471-489, 2021 02 01.
Article en En | MEDLINE | ID: mdl-32833791
ABSTRACT: Initial evidence suggested that people with complex regional pain syndrome (CRPS) have reduced attention to the affected side of their body and the surrounding space, which might be related to pain and other clinical symptoms. Three previous unblinded, uncontrolled studies showed pain relief after treatment with prism adaptation, an intervention that has been used to counter lateralised attention bias in brain-lesioned patients. To provide a robust test of its effectiveness for CRPS, we conducted a double-blind randomized controlled trial of prism adaptation for unilateral upper-limb CRPS-I. Forty-nine eligible adults with CRPS were randomized to undergo 2 weeks of twice-daily home-based prism adaptation treatment (n = 23) or sham treatment (n = 26). Outcomes were assessed in person 4 weeks before and immediately before treatment, and immediately after and 4 weeks after treatment. Long-term postal follow-ups were conducted 3 and 6 months after treatment. We examined the effects of prism adaptation vs sham treatment on current pain intensity and the CRPS symptom severity score (primary outcomes), as well as sensory, motor, and autonomic functions, self-reported psychological functioning, and experimentally tested neuropsychological functions (secondary outcomes). We found no evidence that primary or secondary outcomes differed between the prism adaptation and sham treatment groups when tested at either time point after treatment. Overall, CRPS severity significantly decreased over time for both groups, but we found no benefits of prism adaptation beyond sham treatment. Our findings do not support the efficacy of prism adaptation treatment for relieving upper-limb CRPS-I. This trial was prospectively registered (ISRCTN46828292).
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Distrofia Simpática Refleja / Síndromes de Dolor Regional Complejo Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: Pain Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Distrofia Simpática Refleja / Síndromes de Dolor Regional Complejo Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: Pain Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos